LifeVantage Corporation announced its financial results for the third fiscal quarter of 2025. Revenue during the quarter was $58.4 million, a 21.1% year-over-year increase, with an adjusted EBITDA of $6.4 million, compared to $5.1 million in the same quarter of 2024. Gross profit during the quarter was $47.3 million, or 81% of revenue, up from $38.1 million (78.9% of revenue) in the same quarter of 2024. Net income during the quarter was $3.5 million, or $0.26 per diluted share, up from $1.7 million, or $0.13 per diluted share, in the fiscal third quarter of 2024.
“Third quarter results were strong with revenues up 21% year-over-year to $58.4 million, reflecting robust demand for our MindBody GLP-1 System,” said Steve Fife, LifeVantage President and CEO. “We also delivered another quarter of improving profitability including a 210 basis point improvement in gross margin and 27% increase in adjusted EBITDA. International expansion was a key focus in the quarter with the launch of our Evolve Compensation Plan into the Philippines, Taiwan, Hong Kong and Singapore in early March followed by the launch of the MB System, as our GLP-1 activation product is known outside of the US, into Japan, Australia, New Zealand, Europe, the UK, Mexico, and Thailand. At our annual Global Convention in April, the incredible intensity and engagement of our independent consultants underscored the tremendous growth potential for LifeVantage as our addressable market continues to broaden and we leverage our unique position around activation.”
Cash from operations during the first nine months of fiscal 2025 generated $10.8 million, up from $9.6 million in the same period of fiscal 2024. The company ended the period with cash and cash equivalents of $22.5 million, up from $16.9 million at the end of June 30, 2024, with no outstanding debt.
